EU Drug-Device Combination Rules Are Getting More Systematic

What It Means for Prefilled Syringes and Injection Pens (2026 Update)

As prefilled syringes (PFS), prefilled pens, and autoinjectors become the dominant formats for modern biologics (including GLP-1s), the EU has been tightening and clarifying how these products must be developed, documented, and maintained throughout their lifecycle.

In practice, EU compliance for “drug + device” products is no longer a loose checklist. It is becoming a structured, end-to-end system—covering device conformity evidence, quality documentation, labeling, change control, and post-market responsibilities.

This article explains the EU regulatory logic, the key compliance requirements, and a practical documentation map for companies working with PFS and injection pens.

1) First: What Counts as a “Drug-Device Combination” in the EU?

In the EU, products combining a medicinal product and a device can fall under different rules depending on how they are presented and what the principal mode of action is.

EMA commonly distinguishes:

A) Integral drug-device combinations (iDDC)

Medicine + device form a single integrated product (e.g., many prefilled syringes and prefilled pens/autoinjectors where the medicine is the primary mode of action).

B) Co-packaged or supplied separately

The medicinal product is packaged together with a separate device, or the device is obtained separately but intended for use with the medicine (administration devices). Examples include prefilled syringes/pens (co-packaged scenarios are explicitly referenced by EMA) and other administration devices.

Why this matters: the evidence you must submit (CE certificate vs Notified Body Opinion vs CE marking of the standalone device) can change based on this classification.

2) The Big Shift: MDR Article 117 and the “Notified Body Opinion” Pathway

Under the EU Medical Devices Regulation (EU) 2017/745 (MDR), Article 117 introduced a key expectation for integral drug-device combinations submitted under the medicinal product framework:

• Your marketing authorization dossier should include either a CE certificate / EU declaration of conformity for the device part or (in certain cases) a Notified Body Opinion confirming conformity of the device part to relevant MDR requirements.

• EMA notes this applies since 26 May 2021, with specific exemptions such as certain Class I devices (non-sterile, non-measuring).

In other words: for many prefilled pens and prefilled syringes that are integral combinations, the EU expects a formal third-party conformity assessment outcome (or equivalent evidence route), not just internal statements.

Switzerland’s regulator Swissmedic explicitly aligns its implementation with the EU approach for Article 117 and points applicants toward EMA’s guidance/Q&A—another sign the “systematized” model is spreading beyond the EU.

3) EMA Guidance Is Evolving: More Clarity, More Lifecycle Focus

EMA has been actively updating practical guidance for applicants and notified bodies, including a revised Q&A that covers:

• Integral drug-device combinations (including lifecycle management)

• Co-packaged devices and labeling expectations

• Consultation procedures for devices with ancillary medicinal substances

• Companion diagnostics interfaces

EMA also maintains a Combination Products Operational Group to coordinate regulatory challenges at the intersection of medicines and devices—another signal that this area is now treated as a dedicated regulatory domain, not an edge case.

4) What “Systematized Compliance” Looks Like for PFS / Injection Pens

For PFS and injection pens, EU compliance increasingly means you need a structured package of device evidence embedded into medicinal-product quality submissions and maintained over the full product lifecycle.

Typical “system blocks” reviewers expect to see covered

While exact expectations vary by product type and pathway, companies commonly need to demonstrate:

1. Configuration clarity

• Is it integral, co-packaged, or referenced/supplied separately?

2. Device conformity route

• CE certificate / EU declaration of conformity or Notified Body Opinion (where applicable).

3. Quality documentation integration

• EMA highlights a dedicated guideline on quality documentation for medicines used with a medical device (adopted in 2021; effective date noted by EMA).

4. Labeling and use conditions

• Clear instructions, compatibility statements, and device-related labeling expectations are treated as part of compliant use.

5. Lifecycle change control

• Any device change (materials, supplier, geometry, dose mechanism, labeling, etc.) can trigger regulatory impact analysis and potential updates in the dossier.

5) Practical Checklist: EU-Ready Documentation Flow for Injection Pens / PFS

Here’s a high-level, practical flow many teams use when planning EU submissions (informational only—not legal advice):

Step 1 — Define the combination type

• Integral (iDDC) vs co-packaged vs referenced device.

Step 2 — Confirm the applicable legal framework

• MDR/medicines framework depends on principal mode of action and presentation (EMA Q&A explains the framework split and references MDR Articles 1(8) and 1(9)).

Step 3 — Lock the device conformity strategy early

• CE marking route vs Notified Body Opinion route (Article 117 scenarios).

Step 4 — Build “device evidence” into pharma quality documentation

• Follow EMA’s guideline structure for quality documentation where a medical device is involved.

Step 5 — Plan lifecycle governance

• Device changes, suppliers, labeling updates, usability updates, and complaint trending should be managed as a controlled system aligned with evolving EMA Q&A expectations.

6) Key Takeaways for Brands, CDMOs, and Device Partners

• EU expectations for PFS and injection pens are becoming more explicit and standardized via MDR and EMA guidance.

• For many integral combinations, Article 117 is the compliance “hinge” that connects medicines dossiers with MDR device requirements and Notified Body involvement.

• Winning teams treat the device as a regulated subsystem (documentation + lifecycle), not “just packaging.”